STIL, a Delft company supported by the YES!Delft incubator since 2017, makes an anti-tremor orthosis: a forearm brace whose mechanical dampers absorb the involuntary shaking of people with essential tremor, Parkinson's disease or dystonia while leaving voluntary movement free. It was selected in the EIC Accelerator's January 2023 cut-off for blended finance and received an EU grant of €1.64 million for STABILIS, a €2.34 million project that ran from June 2023 to November 2025, according to CORDIS. Its first orthosis, the company's final report says, "was clinically effective for essential tremor in the forearm" but helped only a subgroup; Stabilis was meant "to serve the entire patient population and covered by health insurance".

The project is closed. Its final report states that the Stabilis device "showed to reduce action tremors for multiple tremor disorders" and that a new method of fitting it was developed, according to the CORDIS reporting page. It also states that "more clinical validation is needed to bring Stabilis into a market-ready shape, and obtain a CE-mark". No CE mark or launch of Stabilis has been announced.

€1.64MEU grant
30M+People with tremor worldwide
€845kCrowdfunding by April 2025
NoCE mark for Stabilis yet

Company file

Legal entity
STIL B.V., Delft
Founders
IJsbrand de Lange, Nicola Pambakian
Products
STIL orthosis (CE-marked); Stabilis (in development)
Distribution
Netherlands, Germany, Belgium, Italy
Investors named
Health Innovations, Rabobank, Brain Foundation Netherlands, EIC
Website
Unreachable when checked, September 2026
EIC funding
Blended finance; €1.64M grant

Where STIL Stands Now

STIL ran a crowdfunding round in April 2025 to "scale internationally, achieve reimbursement in key-markets, and launch their second product", with pledges at €845,000 by 22 April, according to YES!Delft. In May 2025 Silicon Canals reported growth capital of €2 million in its headline, although the article body shows the amount as "€????M", and said STIL had sold hundreds of devices by 2024 with distribution in the Netherlands, Germany, Belgium and Italy. The company's website did not load when checked in September 2026.

"More clinical validation is needed to bring Stabilis into a market-ready shape, and obtain a CE-mark."

STIL, final report to the EIC

The Technology: Damping, Not Drugs

The final report describes STIL's orthosis as "fully mechanical", using joint damping to reduce action tremors. It says drugs suppress "around 50% of the symptoms for half the people" and that surgery works better but is invasive and suits few patients. The company says its current orthosis can cut forearm tremor by more than 80%.

What the EIC Award Promised, and What the Record Shows

The award promised a next-generation orthosis for all tremor patients, reimbursed by insurers. The project built and tested Stabilis and found it reduced tremor across several disorders. It did not produce a certified product or reimbursement, and the report gives no patient numbers or effect sizes for Stabilis.

  1. Stabilis deviceDeliveredDeveloped and tested.
  2. Fitting methodDeliveredPer final report.
  3. CE markNot yetMore validation needed.
  4. Insurance coverageUnverifiedNot announced.

The Money

Silicon Canals reports that STIL has raised €3.6 million from investors including Health Innovations, Rabobank, the EIC Accelerator and the Brain Foundation Netherlands. Whether the EIC Fund invested equity under the blended finance award is not public, and STIL's revenue and losses could not be checked from free sources.

What Cannot Be Checked

Questions for the EIC

How many patients Stabilis was tested on and with what effect, when it will get a CE mark, whether the EIC Fund invested, and how many devices STIL sells are not public.

Why Europe Should Care

More than 30 million people live with tremor, the final report says, and treatments are limited. A non-invasive, insured device would help many. STIL already sells one version; the EIC funded the step to a broader product that is not yet on the market.

What the award promised

A next-generation anti-tremor orthosis for the whole patient population, covered by health insurance.

What the record shows

A tested prototype that needs more clinical validation and a CE mark before it can be sold.

The Verdict

Built, not certified

STIL moved its next product forward with EIC money but did not bring it to market within the project. Its existing brace remains the one patients can buy.

STIL and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.